Roche: presents data for MS
(CercleFinance.com) - Roche today announced new clinical and real-world data for OCREVUS (ocrelizumab), demonstrating its role in the ongoing transformation of care for people living with relapsing or primary progressive multiple sclerosis.
This presentation is made at the 9th joint ECTRIMS-ACTRIMS (European and American Committees for Treatment and Research in Multiple Sclerosis) meeting.
OCREVUS is the first and only disease-modifying therapy in MS to benefit people with both RMS and PPMS, and now has 10 years of follow-up data from its three Phase III trials.
The new data on OCREVUS show that, after 10 years of treatment, 77% of people with relapsing-remitting multiple sclerosis have seen no further progression of disability, and 92% continue to walk unaided.
OCREVUS is the first B-cell therapy approved for RMS and PPMS, and it is remarkable that after 10 years of treatment, a large majority of RMS patients remain free of disease progression, a related source said.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
This presentation is made at the 9th joint ECTRIMS-ACTRIMS (European and American Committees for Treatment and Research in Multiple Sclerosis) meeting.
OCREVUS is the first and only disease-modifying therapy in MS to benefit people with both RMS and PPMS, and now has 10 years of follow-up data from its three Phase III trials.
The new data on OCREVUS show that, after 10 years of treatment, 77% of people with relapsing-remitting multiple sclerosis have seen no further progression of disability, and 92% continue to walk unaided.
OCREVUS is the first B-cell therapy approved for RMS and PPMS, and it is remarkable that after 10 years of treatment, a large majority of RMS patients remain free of disease progression, a related source said.
Copyright (c) 2023 CercleFinance.com. All rights reserved.